Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

PRMT5-MTA-IN-8

Name: PRMT5-MTA-IN-8
Brand: TargetMol
SKU: T218090
Rating: 4.5 (1 reviews)

Copy Product Info

🥰Excellent

Synonyms:

Catalog No. T218090 Copy Product Info

🥰Excellent

PRMT5-MTA-IN-8 is an orally active inhibitor of the PRMT5-MTA complex with an IC50 of 4.4 nM. It effectively inhibits the production of symmetric dimethylarginine (SDMA) within cells and suppresses the proliferation of MTAP-deficient cells. In a mouse model of triple-negative breast cancer, PRMT5-MTA-IN-8 demonstrates antitumor efficacy by inhibiting PRMT5, reducing SDMA levels, and inducing tumor cell apoptosis (Apoptosis). This compound is applicable for research in cancers such as triple-negative breast cancer.

PRMT5-MTA-IN-8

Cas No. 3105952-57-3

Pack Size	Price	USA Stock	Global Stock	Quantity
10 mg	Inquiry	10-14 weeks	10-14 weeks
50 mg	Inquiry	10-14 weeks	10-14 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Product Introduction

Bioactivity

Description	PRMT5-MTA-IN-8 is an orally active inhibitor of the PRMT5-MTA complex with an IC50 of 4.4 nM. It effectively inhibits the production of symmetric dimethylarginine (SDMA) within cells and suppresses the proliferation of MTAP-deficient cells. In a mouse model of triple-negative breast cancer, PRMT5-MTA-IN-8 demonstrates antitumor efficacy by inhibiting PRMT5, reducing SDMA levels, and inducing tumor cell apoptosis (Apoptosis). This compound is applicable for research in cancers such as triple-negative breast cancer.
In vitro	PRMT5-MTA-IN-8 (Compound I-14) inhibits PRMT5-dependent SDMA formation in HCT116 MTAP-null cells with an IC50 of 0.8 nM and suppresses their proliferation with an IC50 of 3.9 nM. In MDA-MB-231 cells, PRMT5-MTA-IN-8 (0.1-1000 nM, 6 days) also inhibits PRMT5-dependent SDMA formation with an IC50 of 0.25 nM, enhancing the thermal stability of PRMT5. Additionally, PRMT5-MTA-IN-8 exhibits high metabolic stability in rat liver microsomes and plasma, with half-lives of 131 and 136 minutes, respectively.
In vivo	PRMT5-MTA-IN-8 (I-14) exhibits antitumor activity in the MDA-MB-231 TNBC xenograft model by orally administered daily at doses of 25-100 mg/kg for 28 days. It achieves this effect through targeted inhibition of PRMT5, reducing SDMA levels, and inducing apoptosis in tumor cells.

Chemical Properties

Molecular Weight	441.28
Formula	C₁₉H₁₇BrN₆O₂
Cas No.	3105952-57-3
Smiles	O=C(C=1C=CC=2N=C(N)C=3C=NN(C3C2C1)C)N(OC)CC4=NC=C(Br)C=C4

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Related Tags: PRMT5-MTA-IN-8 in vivo | PRMT5-MTA-IN-8 in vitro | PRMT5-MTA-IN-8 formula | PRMT5-MTA-IN-8 molecular weight